The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial

AIMS : To investigate the effects of spironolactone on fibrosis and cardiac function in people at increased risk of developing heart failure. METHODS AND RESULTS : Randomized, open-label, blinded-endpoint trial comparing spironolactone (50 mg/day) or control for up to 9 months in people with, or at...

Descripción completa

Detalles Bibliográficos
Autores principales: Cleland, John G F, Ferreira, João Pedro, Mariottoni, Beatrice, Pellicori, Pierpaolo, Cuthbert, Joe, Verdonschot, Job A J, Petutschnigg, Johannes, Ahmed, Fozia Z, Cosmi, Franco, Brunner La Rocca, Hans-Peter, Mamas, Mamas A, Clark, Andrew L, Edelmann, Frank, Pieske, Burkert, Khan, Javed, McDonald, Ken, Rouet, Philippe, Staessen, Jan A, Mujaj, Blerim, González, Arantxa, Diez, Javier, Hazebroek, Mark, Heymans, Stephane, Latini, Roberto, Grojean, Stéphanie, Pizard, Anne, Girerd, Nicolas, Rossignol, Patrick, Collier, Tim J, Zannad, Faiez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878013/
https://www.ncbi.nlm.nih.gov/pubmed/33215209
http://dx.doi.org/10.1093/eurheartj/ehaa758

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878013/
https://www.ncbi.nlm.nih.gov/pubmed/33215209
http://dx.doi.org/10.1093/eurheartj/ehaa758

Ejemplares similares